These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 20129255)

  • 1. Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer.
    Obeidat NA; Pradel FG; Zuckerman IH; DeLisle S; Mullins CD
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):343-54. PubMed ID: 20129255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
    Hsiao FY; Mullins CD; Onukwugha E; Pandya N; Hanna N
    J Am Geriatr Soc; 2011 Sep; 59(9):1717-23. PubMed ID: 21831168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for colorectal cancer.
    Goyle S; Maraveyas A
    Dig Surg; 2005; 22(6):401-14. PubMed ID: 16479107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
    Jackson NA; Barrueco J; Soufi-Mahjoubi R; Marshall J; Mitchell E; Zhang X; Meyerhardt J
    Cancer; 2009 Jun; 115(12):2617-29. PubMed ID: 19382200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
    Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
    J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
    Viel E; Demarchi MF; Chaigneau L; Nguyen T; Legat C; Stein U; Thiery-Vuillemin A; Limat S; Pivot X; Borg C
    Am J Clin Oncol; 2008 Feb; 31(1):89-94. PubMed ID: 18376234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Biologic Agents Among Black and White Medicare Patients in the US With Metastatic Colorectal Cancer.
    Goel S; Negassa A; Acuna-Villaorduna A
    JAMA Netw Open; 2021 Dec; 4(12):e2136378. PubMed ID: 34910154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.
    Meyerhardt JA; Li L; Sanoff HK; Carpenter W; Schrag D
    J Clin Oncol; 2012 Feb; 30(6):608-15. PubMed ID: 22253466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
    Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
    Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer: A Population-Based Observational Study.
    Teng CL; Wang CY; Chen YH; Lin CH; Hwang WL
    PLoS One; 2015; 10(8):e0135673. PubMed ID: 26273837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFIRI chemotherapy for metastatic colorectal cancer patients.
    Kamnerdsupaphon P; Lorvidhaya V; Chitapanarux I; Tonusin A; Sukthomya V
    J Med Assoc Thai; 2007 Oct; 90(10):2121-7. PubMed ID: 18041432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
    Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
    J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
    Souglakos J; Pallis A; Kakolyris S; Mavroudis D; Androulakis N; Kouroussis C; Agelaki S; Xenidis N; Milaki G; Georgoulias V
    Oncology; 2005; 69(5):384-90. PubMed ID: 16319509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.
    Zuckerman IH; Rapp T; Onukwugha E; Davidoff A; Choti MA; Gardner J; Seal B; Mullins CD
    J Am Geriatr Soc; 2009 Aug; 57(8):1403-10. PubMed ID: 19563521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer.
    Sørbye H; Berglund A; Tveit KM; Ogreid D; Wanderås EH; Wentzel-Larsen T; Dahl O; Glimelius B
    Acta Oncol; 2007; 46(7):982-8. PubMed ID: 17917829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
    François E; Berdah JF; Chamorey E; Lesbats G; Teissier E; Codoul JF; Badetti JL; Hébert C; Mari V
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):931-6. PubMed ID: 18273618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
    Tabernero J; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Van Cutsem E; Grothey A; Prausová J; Garcia-Alfonso P; Yamazaki K; Clingan PR; Lonardi S; Kim TW; Simms L; Chang SC; Nasroulah F;
    Lancet Oncol; 2015 May; 16(5):499-508. PubMed ID: 25877855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.